Test | Author | Op. | Year | Country or MA (studies) | Train. | n | Prev (%) | Age (years) | Criterion standard | Sn. (%) (95% CI) | Sp. (%) (95% CI) | LR+ (95% CI) | LR− (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MAPSE < 10 mm | Mjølstad et al. [33] | GP | 2012 | Norway | 8 h. | 92 | NR | 73 | Cardiologist echo. | 83.3 (66.4–92.7) | 77.6 (64.1–87.1) | 3.72a | 0.746a |
LVH (ventricular wall > 13 mm) | Evangelista et al. [34] | GP | 2013 | Spain | NR | 393 | 46 | 71 | Cardiologist echo. | 89.8 (NR) | 98.4 (NR) | 56.1a | 0.114a |
Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 16 | 67 | Cardiologist echo. | 71.4 (63.1–79.7) | 97.4 (96.7–98.6) | 27.5a | 0.29a | |
LVEF < 50–55% | Unlüer et al. [41] | EP | 2014 | Turkey | NR | 133 | 56 | 70 | Cardiologist echo. | 98.7 (91.8–99.9) | 86.2 (74.1–93.4) | 7.15 (3.76–13.6) | 0.015 (0.002–0.109) |
Martindale et al. [55] | EP | 2016 | MA (3) | NR | 325 | 41 | NR | Final diagnosis | 80.6 (72.9–86.9) | 80.6 (74.3–86.0) | 4.1 (2.4–7.2) | 0.24 (0.17–0.35) | |
Shah et al. [42] | EP | 2016 | Haiti | 30 h. | 117 | 40 | 36 | Cardiologist echo. | 93.6 (81.4–98.3) | 100 (93.5–100) | ∞a | 0.064a | |
Farsi et al. [43] | EP | 2017 | Iran | 10 h. | 205 | 51 | 61 | Cardiologist echo. | 89 (81–99) | 96 (90–99) | 22 (8–58) | 0.12 (0.07–0.20) | |
LVEF < 40% | Dehbozorgi et al. [44] | EP | 2019 | Iran | NR | 100 | 28 | 58 | Final diagnosis (AHF) | 100 (88–100) | 88 (78–94) | 8 (4.34–14.74) | 0 |
LV dysfunction | Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 4 | 67 | Cardiologist echo. | 50.0 (30.4–69.6) | 92.7 (91.3–94.2) | 6.85a | 0.539a |
LA dilatation | Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 4 | 67 | Cardiologist echo. | 41.5 (25.2–57.8) | 97.7 (96.8–98.6) | 18.0a | 0.701a |
RVD | Evangelista et al. [34] | GP | 2013 | Spain | NR | 393 | 22 | 71 | Cardiologist echo. | 80.2 (NR) | 98.9 (NR) | 73.9a | 0.200a |
Farsi et al. [43] | EP | 2017 | Iran | 10 h. | 205 | 16 | 61 | Cardiologist echo. | 98 (94–99) | 87 (69–96) | 41 (15–109) | 0.07 (0.02–0.27) | |
RVP | Farsi et al. [43] | EP | 2017 | Iran | 10 h. | 205 | 3 | 61 | Cardiologist echo. | 100 (52–100) | 100 (98–100) | ∞a | 0a |
Aortic valve sclerosis | Evangelista et al. [34] | GP | 2013 | Spain | NR | 393 | 23 | 71 | Cardiologist echo. | 81.6 (NR) | 98.2 (NR) | 45.3a | 0.187a |
Aortic stenosis | Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 5 | 67 | Cardiologist echo. | 50.0 (36.1–64.0) | 98.1 (97.0–99.1) | 26.3a | 0.510a |
Aortic insufficiency | Evangelista et al. [34] | GP | 2013 | Spain | NR | 393 | 27 | 71 | Cardiologist echo. | 86.1 (NR) | 95.7 (NR) | 76.9a | 0.145a |
Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 4 | 67 | Cardiologist echo. | 58.3 (43.3–73.3) | 99.0 (98.3–99.6) | 58.3a | 0.421a | |
Dilated ascending aorta | Evangelista et al. [34] | GP | 2013 | Spain | NR | 393 | 15 | 71 | Cardiologist echo. | 89.1 (NR) | 100 (NR) | ∞a | 0.109a |
Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 9 | 67 | Cardiologist echo. | 54.1 (37.1–70.2) | 99.1 (98.4–99.6) | 60.1a | 0.463a | |
Mitral insufficiency | Evangelista et al. [34] | GP | 2013 | Spain | NR | 393 | 48 | 71 | Cardiologist echo. | 89.1 (NR) | 87.2 (NR) | 6.96a | 0.125a |
Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 6 | 67 | Cardiologist echo. | 72.7 (61.2–84.2) | 97.7 (96.8–98.6) | 31.6a | 0.279a | |
Mitral stenosis | Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 1 | 67 | Cardiologist echo. | 62.8 (22.7–100) | 98.1 (97.3–98.9) | 33.1a | 0.379a |
Tricuspid insufficiency | Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 4 | 67 | Cardiologist echo. | 41.4 (21.7–61.0) | 98.9 (98.3–99.5) | 37.6a | 0.694a |
Hypertrophic cardiomyopathy | Evangelista et al. [35] | GP | 2016 | Spain | NR | 1312 | 1 | 67 | Cardiologist echo. | 44.4 (6.4–82.5) | 99.8 (99.6–100) | 222a | 0.557a |
Diastolic heart failure | Unlüer et al. [47] | EP | 2012 | Turkey | 6 h. | 69 | 74 | 63 | Cardiologist echo. | 89 (77–95) | 80 (51–95) | 4.5 (1.6–12) | 0.14 (0.06–0.21) |
Ehrman et al. [48] | EP | 2015 | USA | 3 h. | 62 | 52 | 56 | Cardiologist echo. | 92 (60–100) | 69 (50–83) | 2.9 | 0.12 | |
Restrictive mitral pattern | Nazerian et al. [50] | EP | 2010 | Italy | 4 h. | 125 | 35 | 78 | Final diagnosis of AHF | 82 (73–87) | 90 (84–94) | 8.27 (4.57–15.42) | 0.21 (0.14–0.32) |
Wall motion abnormality | Farsi et al. [43] | EP | 2017 | Iran | 10 t. | 205 | 33 | 61 | Cardiologist echo. | 97 (89–99) | 87% (80–92) | 8 (5–12) | 0.03 (0.01–0.13) |
Croft et al. [52] | EP | 2019 | USA | NR | 75 | 62 | 65 | Cardiologist echo. or ventriculogram | 88 (75–96) | 92 (75–99) | 11.5 (3.1–43.7) | 0.13 (0.05–0.29) | |
Speckle tracking | Reardon et al. [53] | EP | 2018 | USA | NR | 75 | 16 | 52 | Cardiologist echo. or final diagnosis ACS | 29 (17–46) | 88 (72–96) | 2.4a | 0.81a |
Pericardial effusion | Mandavia et al. [54] | EP | 2001 | USA | 5 h. | 515 | 20 | NR | Cardiologist echo. | 96.0 (90.4–98.9) | 98.0 (95.8 to 99.1) | 48.0a | 0.0408a |
Farsi et al. [43] | EP | 2017 | Iran | 10 h. | 205 | 10 | 61 | Cardiologist echo. | 86 (63–96) | 96 (91–98) | 20 (10–40) | 0.15 (0.05–0.40) | |
Shah et al. [42] | EP | 2016 | Haiti | 30 h. | 117 | 8 | 36 | Cardiologist echo. | 88.9 (50.7–99.4) | 99.1 (94.2–100) | 98.8a | 0.112a | |
Bustam et al. [39] | EP | 2014 | Malaysia | 3 h. | 100 | 5 | NR | Cardiologist echo. | 60 (15a–95a) | 100 (96a–100a) | ∞a | 0.40a |